#Sweden #Orexo #Uppsala #OX640 #EAACI

Orexo to Present Innovative OX640 Clinical Research at EAACI Congress

Orexo AB, a leading pharmaceutical company based in Sweden, has announced its attendance at the upcoming 2025 EAACI Congress from June 13-16 in Glasgow, UK. The congress will serve as a pivotal platform for discussing advances in allergy and clinical immunology, gathering over 16,000 professionals across 125 countries.

Orexo is gearing up to share key findings from the OX640-002 clinical study on June 15, presented by Dr. Anne K. Ellis, an esteemed professor at Queen's University and advisor to Orexo. One of the standout aspects of this presentation will be data indicating that epinephrine, a critical component in treating severe allergic reactions, is absorbed significantly faster under conditions mimicking allergic rhinitis than under normal conditions. This finding underscores the rapid onset of action that OX640 offers, especially for patients exhibiting airway symptoms during allergic reactions.

Understanding OX640 and its Significance

OX640 is a nasal powder-based rescue medication formulated with epinephrine specifically designed for acute management of severe allergic reactions, including anaphylaxis. This drug leverages Orexo’s proprietary AmorphOX® technology, which ensures not only a quick absorption of the medication but also boasts impressive stability under varied environmental conditions, allowing for easier storage and extended shelf life.

The OX640-002 clinical study has been a multi-phase investigation engaging 30 participants who have demonstrated otherwise healthy conditions yet suffer from seasonal allergic rhinitis. Throughout the study, epinephrine plasma levels were monitored alongside essential health metrics such as blood pressure and heart rate, particularly in scenarios of acute allergic responses. Notably, this research includes critical data collected after the administration of OX640 in the presence of allergens, effectively simulating real-life conditions that allergy sufferers might face.

The Road Ahead

Robert Rönn, Orexo's Senior Vice President and Head of Research and Development, expressed optimism regarding the data emerging from the OX640 study, highlighting the potential of OX640 to become a game-changer in the allergy treatment landscape. He remarked, “Thanks to our powder-based drug-delivery technology, we are able to present strong data alongside a leading stability profile. I am confident OX640 can emerge as a reliable and convenient rescue solution for those at risk of severe allergic reactions.”

Orexo has spent the past 30 years focusing on developing innovative drug solutions that effectively address significant unmet medical needs. With a strong foothold on the US market through treatments aimed at opioid use disorder and other key therapeutic areas being developed globally, the company's vision continues to align with global health demands.

As the EAACI Congress approaches, all eyes will be on Orexo as it promises to bring forth compelling research that could reshape the treatment landscape for allergy sufferers. Attendees and stakeholders eagerly await details that could position OX640 as a vital tool in managing severe allergic reactions more efficiently and effectively.

To find out more about Orexo’s initiatives and innovative products, visit www.orexo.com or follow them on social media platforms including X, LinkedIn, and YouTube.